AGN up +0.41% percent Today $AGN High is at 198.58 and the Low 195.06 with current volume of 295,234.
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant" to acquire Allergan.
AGN: 197.37 (+1.16), VRX.TO: 150.12 (-0.03)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), ACT: 244.74 (+3.11), VRX: 133.02 (+1.12)
Allergan Has Returned 18.0% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Thu Nov 13, 11:14AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 17.97% as of today's recent price of $197.14.
AGN: 197.37 (+1.16)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.37 (+1.16), JNJ: 108.29 (-0.78), GILD: 101.76 (-2.44), ABBV: 63.46 (-0.17)
FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 197.37 (+1.16)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 197.37 (+1.16), ACT: 244.74 (+3.11)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 197.37 (+1.16), ABBV: 63.45 (-0.18), SNY: 46.56 (+0.03), REGN: 394.62 (-8.01)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), HLF: 37.64 (-0.21), VRX: 133.02 (+1.12), PFE: 30.23 (-0.19), MRK: 58.80 (-0.74), LLY: 67.21 (-0.47)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 197.37 (+1.16), ACT: 244.76 (+3.13), IRWD: 13.06 (-0.43), CBST: 69.77 (-1.97), PFE: 30.23 (-0.19)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 76.91 (-0.42), SJR: 26.49 (+0.08), PRGO: 153.79 (-1.74), XYL: 37.40 (-0.05), CHRW: 73.41 (+0.30), MDLZ: 38.33 (+0.10), MKC: 72.88 (-0.38), MDU: 25.11 (+0.11), SYY: 38.68 (-0.06), PDCO: 45.17 (-0.53), PNR: 68.61 (+0.14), TRI: 38.16 (+0.08), UPS: 107.06 (-0.73), PEP: 97.97 (-0.57), AGN: 197.37 (+1.16), MSI: 64.89 (+0.46), NOV: 71.02 (-0.50), NWN: 46.60 (-0.12), EGN: 67.62 (+0.66), EBAY: 54.24 (-0.13), QCOM: 70.77 (+0.12), AMAT: 22.89 (+0.27), ACN: 84.55 (+0.11), AAPL: 113.96 (+1.14), MA: 84.15 (-0.05), SCHW: 28.88 (+0.09), STR: 23.49 (-0.27), SE: 37.86 (unch), GAS: 51.59 (-0.06), IRM: 37.99 (-0.38), WM: 49.12 (-0.25), CMP: 88.64 (+0.27), VRSK: 63.12 (-0.04), GILD: 101.77 (-2.43), EXPD: 43.95 (+0.05), TFX: 115.05 (+0.41), CVS: 89.38 (-0.75), PG: 88.37 (-0.23), PX: 126.06 (-0.67), NVS: 93.98 (-0.40)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 197.37 (+1.16)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.37 (+1.16), GILD: 101.77 (-2.43), ABBV: 63.45 (-0.18), BMY: 57.64 (-0.16)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.76 (+3.13)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.27 (-0.94), AGN: 197.37 (+1.16), JNJ: 108.30 (-0.77), DNDN: 0.12 (-0.01)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 197.37 (+1.16), ZTS: 43.09 (-0.15), ACT: 244.76 (+3.13), VRX: 133.02 (+1.12)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 197.37 (+1.16), ACT: 244.76 (+3.13), VRX: 133.02 (+1.12), MDT: 68.88 (-0.50), SLXP: 98.84 (+1.85), SNY: 46.56 (+0.03)
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Physicians Continue to Voice Strong Support for Allergan via Open Letters to the Eye Care Community
Business Wire - Fri Nov 14, 8:00AM CST
Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company"
today announced results from a recent survey of eye care professionals and the availability of an open letter website in response to requests from physician customers for a platform to voice their concerns regarding the unsolicited proposal from Valeant Pharmaceuticals International, Inc. ("Valeant" to acquire Allergan. AGN: 197.37 (+1.16), VRX.TO: 150.12 (-0.03)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), ACT: 244.74 (+3.11), VRX: 133.02 (+1.12)
Allergan Has Returned 18.0% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Thu Nov 13, 11:14AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 17.97% as of today's recent price of $197.14.
AGN: 197.37 (+1.16)
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.37 (+1.16), JNJ: 108.29 (-0.78), GILD: 101.76 (-2.44), ABBV: 63.46 (-0.17)
FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 197.37 (+1.16)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.74 (+3.11)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 197.37 (+1.16), ACT: 244.74 (+3.11)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 197.37 (+1.16), ABBV: 63.45 (-0.18), SNY: 46.56 (+0.03), REGN: 394.62 (-8.01)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.09 (-0.15), AGN: 197.37 (+1.16), HLF: 37.64 (-0.21), VRX: 133.02 (+1.12), PFE: 30.23 (-0.19), MRK: 58.80 (-0.74), LLY: 67.21 (-0.47)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 197.37 (+1.16), ACT: 244.76 (+3.13), IRWD: 13.06 (-0.43), CBST: 69.77 (-1.97), PFE: 30.23 (-0.19)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 76.91 (-0.42), SJR: 26.49 (+0.08), PRGO: 153.79 (-1.74), XYL: 37.40 (-0.05), CHRW: 73.41 (+0.30), MDLZ: 38.33 (+0.10), MKC: 72.88 (-0.38), MDU: 25.11 (+0.11), SYY: 38.68 (-0.06), PDCO: 45.17 (-0.53), PNR: 68.61 (+0.14), TRI: 38.16 (+0.08), UPS: 107.06 (-0.73), PEP: 97.97 (-0.57), AGN: 197.37 (+1.16), MSI: 64.89 (+0.46), NOV: 71.02 (-0.50), NWN: 46.60 (-0.12), EGN: 67.62 (+0.66), EBAY: 54.24 (-0.13), QCOM: 70.77 (+0.12), AMAT: 22.89 (+0.27), ACN: 84.55 (+0.11), AAPL: 113.96 (+1.14), MA: 84.15 (-0.05), SCHW: 28.88 (+0.09), STR: 23.49 (-0.27), SE: 37.86 (unch), GAS: 51.59 (-0.06), IRM: 37.99 (-0.38), WM: 49.12 (-0.25), CMP: 88.64 (+0.27), VRSK: 63.12 (-0.04), GILD: 101.77 (-2.43), EXPD: 43.95 (+0.05), TFX: 115.05 (+0.41), CVS: 89.38 (-0.75), PG: 88.37 (-0.23), PX: 126.06 (-0.67), NVS: 93.98 (-0.40)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 197.37 (+1.16)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.37 (+1.16), GILD: 101.77 (-2.43), ABBV: 63.45 (-0.18), BMY: 57.64 (-0.16)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 197.37 (+1.16), VRX: 133.02 (+1.12), ACT: 244.76 (+3.13)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.27 (-0.94), AGN: 197.37 (+1.16), JNJ: 108.30 (-0.77), DNDN: 0.12 (-0.01)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 197.37 (+1.16), ZTS: 43.09 (-0.15), ACT: 244.76 (+3.13), VRX: 133.02 (+1.12)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.75 (unch), AGN: 197.37 (+1.16), ACT: 244.76 (+3.13), VRX: 133.02 (+1.12), MDT: 68.88 (-0.50), SLXP: 98.84 (+1.85), SNY: 46.56 (+0.03)
